When it comes to their bid for Allergan, hostile isn't the preferred approach for Valeant and takeover partner Bill Ackman, CEO J. Michael Pearson told investors Tuesday. But it's the one the team is going with.
written on 17.06.2014
Another hostile step for Valeant in its hot pursuit of Allergan
